ACXP Relative Valuation
ACXP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ACXP is overvalued; if below, it's undervalued.
Historical Valuation
Acurx Pharmaceuticals Inc (ACXP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.35. The fair price of Acurx Pharmaceuticals Inc (ACXP) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：2.91
Fair
-0.58
PE
1Y
3Y
5Y
0.02
EV/EBITDA
Acurx Pharmaceuticals Inc. (ACXP) has a current EV/EBITDA of 0.02. The 5-year average EV/EBITDA is -0.05. The thresholds are as follows: Strongly Undervalued below -0.36, Undervalued between -0.36 and -0.20, Fairly Valued between 0.10 and -0.20, Overvalued between 0.10 and 0.26, and Strongly Overvalued above 0.26. The current Forward EV/EBITDA of 0.02 falls within the Historic Trend Line -Fairly Valued range.
0.01
EV/EBIT
Acurx Pharmaceuticals Inc. (ACXP) has a current EV/EBIT of 0.01. The 5-year average EV/EBIT is -1.61. The thresholds are as follows: Strongly Undervalued below -3.68, Undervalued between -3.68 and -2.65, Fairly Valued between -0.58 and -2.65, Overvalued between -0.58 and 0.45, and Strongly Overvalued above 0.45. The current Forward EV/EBIT of 0.01 falls within the Overvalued range.
0.00
PS
Acurx Pharmaceuticals Inc. (ACXP) has a current PS of 0.00. The 5-year average PS is 0.03. The thresholds are as follows: Strongly Undervalued below -0.44, Undervalued between -0.44 and -0.21, Fairly Valued between 0.27 and -0.21, Overvalued between 0.27 and 0.51, and Strongly Overvalued above 0.51. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.59
P/OCF
Acurx Pharmaceuticals Inc. (ACXP) has a current P/OCF of -0.59. The 5-year average P/OCF is -5.49. The thresholds are as follows: Strongly Undervalued below -44.55, Undervalued between -44.55 and -25.02, Fairly Valued between 14.04 and -25.02, Overvalued between 14.04 and 33.57, and Strongly Overvalued above 33.57. The current Forward P/OCF of -0.59 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Acurx Pharmaceuticals Inc. (ACXP) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.95. The thresholds are as follows: Strongly Undervalued below -3.67, Undervalued between -3.67 and -2.31, Fairly Valued between 0.41 and -2.31, Overvalued between 0.41 and 1.77, and Strongly Overvalued above 1.77. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Acurx Pharmaceuticals Inc (ACXP) has a current Price-to-Book (P/B) ratio of 1.37. Compared to its 3-year average P/B ratio of 6.66 , the current P/B ratio is approximately -79.49% higher. Relative to its 5-year average P/B ratio of 5.71, the current P/B ratio is about -76.06% higher. Acurx Pharmaceuticals Inc (ACXP) has a Forward Free Cash Flow (FCF) yield of approximately -136.45%. Compared to its 3-year average FCF yield of -53.27%, the current FCF yield is approximately 156.15% lower. Relative to its 5-year average FCF yield of -39.88% , the current FCF yield is about 242.17% lower.
1.37
P/B
Median3y
6.66
Median5y
5.71
-136.45
FCF Yield
Median3y
-53.27
Median5y
-39.88
Competitors Valuation Multiple
The average P/S ratio for ACXP's competitors is 0.07, providing a benchmark for relative valuation. Acurx Pharmaceuticals Inc Corp (ACXP) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ACXP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ACXP in the past 1 year is driven by Unknown.
People Also Watch
JDZG
JIADE Ltd
0.76USD
-1.30%
NNVC
NanoViricides, Inc
1.24USD
-3.13%
EDTK
Skillful Craftsman Education Technology Ltd
1USD
5.82%
ABVE
Above Food Ingredients Inc
2.46USD
37.43%
MLGO
MicroAlgo Inc
5.47USD
5.39%
LIQT
LiqTech International Inc
1.8USD
2.27%
SYBX
Synlogic Inc
1.18USD
-0.84%
EQS
EQUUS Total Return Inc
1.325USD
0.38%
BTAI
BioXcel Therapeutics Inc
2.04USD
17.24%
Frequently Asked Questions
Is Acurx Pharmaceuticals Inc (ACXP) currently overvalued or undervalued?
Acurx Pharmaceuticals Inc (ACXP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.35. The fair price of Acurx Pharmaceuticals Inc (ACXP) is between to according to relative valuation methord.
What is Acurx Pharmaceuticals Inc (ACXP) fair value?
ACXP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Acurx Pharmaceuticals Inc (ACXP) is between to according to relative valuation methord.
How does ACXP's valuation metrics compare to the industry average?
The average P/S ratio for ACXP's competitors is 0.07, providing a benchmark for relative valuation. Acurx Pharmaceuticals Inc Corp (ACXP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Acurx Pharmaceuticals Inc (ACXP) as of Jan 08 2026?
As of Jan 08 2026, Acurx Pharmaceuticals Inc (ACXP) has a P/B ratio of 1.37. This indicates that the market values ACXP at 1.37 times its book value.
What is the current FCF Yield for Acurx Pharmaceuticals Inc (ACXP) as of Jan 08 2026?
As of Jan 08 2026, Acurx Pharmaceuticals Inc (ACXP) has a FCF Yield of -136.45%. This means that for every dollar of Acurx Pharmaceuticals Inc’s market capitalization, the company generates -136.45 cents in free cash flow.
What is the current Forward P/E ratio for Acurx Pharmaceuticals Inc (ACXP) as of Jan 08 2026?
As of Jan 08 2026, Acurx Pharmaceuticals Inc (ACXP) has a Forward P/E ratio of -0.58. This means the market is willing to pay $-0.58 for every dollar of Acurx Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Acurx Pharmaceuticals Inc (ACXP) as of Jan 08 2026?
As of Jan 08 2026, Acurx Pharmaceuticals Inc (ACXP) has a Forward P/S ratio of 0.00. This means the market is valuing ACXP at $0.00 for every dollar of expected revenue over the next 12 months.